Alan David Borthwick,Mark Trevor Mills,Jane Theresa Brown,Jonathan Patrick Thomas Corcoran,Maria Beatriz De Castro Vasconcelos Goncalves,Sarkis Barret Kalindjian
申请号：
US16536441
公开号：
US10752616B2
申请日:
2019.08.09
申请国别(地区):
US
年份:
2020
代理人:
摘要：
The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain bicycloheteroaryl-heteroaryl-benzoic acid compounds of the following formula (for convenience, collectively referred to herein as “BHBA compounds”), which, inter alia, are (selective) retinoic acid receptor beta (RARβ) (e.g., RARβ2) agonists. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to (selectively) activate RARβ (e.g., RARβ2), to cause or promote neurite development, neurite outgrowth, and/or neurite regeneration, and in the treatment of diseases and conditions that are mediated by RARβ (e.g., RARβ2), that are ameliorated by the activation of RARβ (e.g., RARβ2), etc., including, e.g., neurological injuries such as spinal cord injuries.
